Advertisement
Screener

CHAMPIONS ONCOLOGY, INC. (CSBR) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

2.8 / 5 stars · 68/120 Roast Me

CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-04-30 was 71.60K shares.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-01-31 was 6.67K shares.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-10-31 was 105.14K shares, a 8.22% decline year-over-year.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-07-31 was 0.00 shares, a 100.00% decline year-over-year.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 109.66K shares, a 40.21% decline from fiscal 2025.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 183.40K shares, a 17.98% increase from fiscal 2024.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 155.45K shares, a 329.31% increase from fiscal 2023.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 36.21K shares, a 66.59% decline from fiscal 2022.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2026-04-30109.66K shares
10-K · filed 2026-07-27
2025-04-3071.60K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23
183.40K shares
10-K · filed 2025-07-23
2025-01-316.67K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17
111.80K shares
derived: sum of 4 quarters · filed 2025-07-23
2024-10-31105.14K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-16
105.14K shares
derived: sum of 4 quarters · filed 2025-07-23
2024-07-310.00 shares
10-Q · filed 2024-09-13
114.55K shares
derived: sum of 4 quarters · filed 2025-07-23
2024-04-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23
155.45K shares
10-K · filed 2025-07-23
2024-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-15
155.45K shares
derived: sum of 4 quarters · filed 2024-07-19
2023-10-31114.55K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-13
155.45K shares
derived: sum of 4 quarters · filed 2024-07-19
2023-07-3140.90K shares
10-Q · filed 2023-09-13
2023-04-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19
36.21K shares
10-K · filed 2024-07-19
2023-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16
2022-04-304.50K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24
108.38K shares
10-K · filed 2023-07-24
2022-01-3121.80K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15
127.77K shares
derived: sum of 4 quarters · filed 2022-07-22
2021-10-3181.08K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13
127.60K shares
derived: sum of 4 quarters · filed 2022-07-22
2021-07-311.00K shares
10-Q · filed 2021-09-13
687.18K shares
derived: sum of 4 quarters · filed 2022-07-22
2021-04-3023.89K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-22
687.34K shares
10-K · filed 2022-07-22
2021-01-3121.63K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-03-15
708.20K shares
derived: sum of 4 quarters · filed 2021-07-26
2020-10-31640.66K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-12-14
889.69K shares
derived: sum of 4 quarters · filed 2021-07-26
2020-07-311.16K shares
10-Q · filed 2020-09-14
249.66K shares
derived: sum of 4 quarters · filed 2021-07-26
2020-04-3044.76K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-26
248.50K shares
10-K · filed 2021-07-26
2020-01-31203.11K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-03-16
209.88K shares
derived: sum of 4 quarters · filed 2020-07-28
2019-10-31625.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-12-16
-16.92K shares
derived: sum of 4 quarters · filed 2020-07-28
2019-07-310.00 shares
10-Q · filed 2019-09-16
343.38K shares
derived: sum of 4 quarters · filed 2020-07-28
2019-04-306.14K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-28
363.38K shares
10-K · filed 2020-07-28
2019-01-31-23.68K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18
357.24K shares
derived: sum of 4 quarters · filed 2019-07-29
2018-10-31360.93K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-12-17
393.43K shares
derived: sum of 4 quarters · filed 2019-07-29
2018-07-3120.00K shares
10-Q · filed 2018-09-14
32.50K shares
derived: sum of 4 quarters · filed 2019-07-29
2018-04-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-07-29
12.50K shares
10-K · filed 2019-07-29
2018-01-3112.50K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-19
12.50K shares
derived: sum of 4 quarters · filed 2018-07-30
2017-10-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-12-15
0.00 shares
derived: sum of 4 quarters · filed 2018-07-30
2017-07-310.00 shares
10-Q · filed 2017-09-14
0.00 shares
derived: sum of 4 quarters · filed 2018-07-30
2017-04-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-30
0.00 shares
10-K · filed 2018-07-30
2017-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-03-17
0.00 shares
derived: sum of 4 quarters · filed 2017-07-28
2016-10-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-12-14
0.00 shares
derived: sum of 4 quarters · filed 2017-07-28
2016-07-310.00 shares
10-Q · filed 2016-09-14
0.00 shares
derived: sum of 4 quarters · filed 2017-07-28
2016-04-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28
0.00 shares
10-K · filed 2017-07-28
2016-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-16
-3.44K shares
derived: sum of 4 quarters · filed 2016-07-29
2015-10-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-12-15
-3.44K shares
derived: sum of 4 quarters · filed 2016-07-29
2015-07-310.00 shares
10-Q · filed 2015-09-11
2015-04-30-3.44K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29
313.00 shares
10-K · filed 2016-07-29
2015-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-17
2014-04-3018.75K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-29
33.75K shares
10-K · filed 2015-07-29
2014-01-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-14
2013-04-300.00 shares
10-K · filed 2014-07-28
2012-10-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-12-13
2012-07-310.00 shares
10-Q · filed 2012-09-12
2012-04-3050.00K shares
10-K · filed 2013-07-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioStem Technologies, Inc. (BSEM)United States$0.069B
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Vaxart, Inc. (VXRT)United States$0.080B3.84
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48